Professor Feng-ming Spring KONG

Professor Spring Feng-ming KONG

Clinical Professor
Director, Imaging and Blood Biomarker Group

  • MD, PhD
Short Biography

Feng-Ming (Spring) Kong, MD, PhD, Master in clinical trial design and data analysis, American Board Certified Radiation Oncologist, Fellow of the American College of Radiology (FACR), Fellow of the American Association of Women Radiologists (FAAWR) and Fellow of American Society for Radiation Oncology (FASTRO), is a clinical professor, Director of Imaging and Blood Biomarker Group, Director of Thoracic Oncology Center and Deputy Cancer Center Director, HKU Shen-Zhen Hospital, Li Ka Shing faculty of Medicine, the University of Hong Kong. Professor Kong is a graduate of Radiation Oncology Residency Program from the Washington University in St. Louis  and also had Radiation Oncology Residency training from Shanghai Cancer Hospital/Fudan University and postdoctoral training at Duke University. As a radiation oncologist in United States, Professor Kong has served as an expert panelist of National Cancer Network (NCCN) Guideline and ACR radiation oncology practice appropriateness guidelines. Dr. Kong received numerous awards including prestigious young investigator award and career developmental award from American Society of Clinical Oncology (ASCO), NIH R21 and R01 as the Principal Investigator and P01 as a Key Investigator from NIH/NCI of the United States. Professor Kong served as the leader of thoracic radiation oncology research program, director of Clinical Research, Chair of Radiation Oncology Department and associate director of Cancer Center, Co-Leader of MultiD Thoracic Oncology Program. She served as the President of American Association for Women Radiologists Radiation Oncologists. During her tenure in Hong Kong China, she has secured funding of 40+ million RMB including China NSF and a platform grant of high-level talents on clinical trial. Upto October 2023, Professor Kong has published 280 scientific publications, with over 10,000 citations, was listed among the top 1% scientists in the field of lung cancer in 2020 and 1% published in radiation pneumonitis in 2021. Professor Kong has served as a reviewer for more than 20 Journals, and served as a member of editorial boards of top oncology journals like Journal of Clinical Oncology (JCO, IF 50s in 2023) and the best Radiation Oncology Journal, the International Journal of Radiation Oncology (Red Journal,IF8.0). She is currently as an associate editor of the Journal of the National Cancer Centre (JNCC), the official Journal of China Health administration commission, Co-Editor-in-Chief for Intelligent Oncology sponsored the Chinese Anti-Cancer Association and editorial roles in other journals like frontier Oncology. She is the founding President of the Sino-American Network of Radiation Oncology (SANTRO), the inaugural Chair of the SANTRO Board Directors. Professor Kong is Chair of the WHO STAR Oncology Guidelines Assessment Commission of the WHO Collaborating Centre, and the President of the Global Cancer Collaborative Group (GCOG). 

Selected Publications

    1: Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, Cheung ALY, Lee VWY, Lau VWH, El Helali A, Man K, Kong FMS, Lo CM, Chan AC. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single- arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):169-178. doi: 10.1016/S2468-1253(22)00339-9. Epub 2022 Dec 15. PMID: 36529152.

    2: Chen WW, Chu TSM, Xu L, Zhao CN, Poon WS, Leung GK, Kong FS*. Immune related biomarkers for cancer metastasis to the brain. Exp Hematol Oncol. 2022 Dec 16;11(1):105. doi: 10.1186/s40164-022-00349-z. PMID: 36527157; PMCID: PMC9756766.

    3: Ruan J, Zhao Z, Qian Y, Xu R, Liao G, Kong FS*. The predictive role of soluble programmed death ligand 1 in digestive system cancers. Front Oncol. 2023 Jul 13;13:1170220. doi: 10.3389/fonc.2023.1170220. PMID: 37519785; PMCID: PMC10374258.

    4: Milano MT, Doucette C, Mavroidis P, Yorke E, Ryckman J, Mahadevan A, Kapitanova I, Kong FS, Grimm J, Marks LB. Hypofractionated Stereotactic Radiation Therapy Dosimetric Tolerances for the Inferior Aspect of the Brachial Plexus: A Systematic Review. Int J Radiat Oncol Biol Phys. 2023 Jan 20:S0360-3016(22)03525-8. doi: 10.1016/j.ijrobp.2022.11.012. Epub ahead of print. PMID: 36682981.

    5: Meng Y, Sun H, Wang S, Yang H, Kong FS*. Treatment-Related Pneumonitis of EGFR Tyrosine Kinase Inhibitors Plus Thoracic Radiation Therapy in Patients With Non- Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys. 2023 Sep 14:S0360-3016(23)07917-8. doi: 10.1016/j.ijrobp.2023.09.009. Epub ahead of print. PMID: 37716460.

    6: Yang D, Ren G, Ni R, Huang YH, Lam NFD, Sun H, Wan SBN, Wong MFE, Chan KK, Tsang HCH, Xu L, Wu TC, Kong FS, Wáng YXJ, Qin J, Chan LWC, Ying M, Cai J. Deep learning attention-guided radiomics for COVID-19 chest radiograph classification. Quant Imaging Med Surg. 2023 Feb 1;13(2):572-584. doi: 10.21037/qims-22-531. Epub 2022 Nov 21. PMID: 36819269; PMCID: PMC9929417.

    7: Chen F, Ma L, Wang Q, Zhou M, Nong Y, Jing H, Han Y, Liu Y, Hu Y, Yu H, Fu P, Kong FS*. Chemotherapy is a risk factor of lymphopenia before adjuvant radiotherapy in breast cancer. Cancer Rep (Hoboken). 2022 Jul;5(7):e1525. doi: 10.1002/cnr2.1525. Epub 2021 Aug 14. PMID: 34390318; PMCID: PMC9327667.

    8: Milano MT, Mavroidis P, Ryckman J, Yorke E, Doucette C, Mahadevan A, Kapitanova I, Spring Kong FM, Marks LB, Grimm J. Radiation-induced inferior brachial plexopathy after stereotactic body radiotherapy: Pooled analyses of risks. Radiother Oncol. 2023 May;182:109583. doi: 10.1016/j.radonc.2023.109583. Epub 2023 Feb 25. PMID: 36842665; PMCID: PMC10501316.

    9: Sun H, Ren G, Teng X, Song L, Li K, Yang J, Hu X, Zhan Y, Wan SBN, Wong MFE, Chan KK, Tsang HCH, Xu L, Wu TC, Kong FS, Wang YXJ, Qin J, Chan WCL, Ying M, Cai J. Artificial intelligence-assisted multistrategy image enhancement of chest X-rays for COVID-19 classification. Quant Imaging Med Surg. 2023 Jan 1;13(1):394-416. doi: 10.21037/qims-22-610. Epub 2022 Nov 10. PMID: 36620146; PMCID: PMC9816729.

    10: Ren G, Li B, Lam SK, Xiao H, Huang YH, Cheung AL, Lu Y, Mao R, Ge H, Kong FS, Ho WY, Cai J. A Transfer Learning Framework for Deep Learning-Based CT-to- Perfusion Mapping on Lung Cancer Patients. Front Oncol. 2022 Jul 1;12:883516. doi: 10.3389/fonc.2022.883516. PMID: 35847874; PMCID: PMC9283770.

    11: Zhang J, Teng X, Lam S, Sun J, Cheung AL, Ng SC, Lee FK, Au KH, Yip CW, Lee VH, Lin Z, Liang Y, Yang R, Han Y, Zhang Y, Kong FS, Cai J. Quantitative Spatial Characterization of Lymph Node Tumor for N Stage Improvement of Nasopharyngeal Carcinoma Patients. Cancers (Basel). 2022 Dec 30;15(1):230. doi: 10.3390/cancers15010230. PMID: 36612236; PMCID: PMC9818273.

    12: Huang YH, Ren G, Xiao H, Yang D, Kong FS, Ho WY, Cai J. Volumetric multiphase ventilation imaging based on four-dimensional computed tomography for functional lung avoidance radiotherapy. Med Phys. 2022 Nov;49(11):7237-7246. doi: 10.1002/mp.15847. Epub 2022 Jul 22. PMID: 35841346.

    13: Huang YH, Teng X, Zhang J, Chen Z, Ma Z, Ren G, Kong FS, Ge H, Cai J. Respiratory Invariant Textures From Static Computed Tomography Scans for Explainable Lung Function Characterization. J Thorac Imaging. 2023 Sep 1;38(5):286-296. doi: 10.1097/RTI.0000000000000717. Epub 2023 May 29. PMID: 37265243.

    14: Lam NFD, Sun H, Song L, Yang D, Zhi S, Ren G, Chou PH, Wan SBN, Wong MFE, Chan KK, Tsang HCH, Kong FS, Wáng YXJ, Qin J, Chan LWC, Ying M, Cai J. Development and validation of bone-suppressed deep learning classification of COVID-19 presentation in chest radiographs. Quant Imaging Med Surg. 2022 Jul;12(7):3917-3931. doi: 10.21037/qims-21-791. PMID: 35782269; PMCID: PMC9246721.

    15: Lan Y, Pi W, Zhou Z, Meng Y, DanMei, Xu Y, Xia X, WeiWang, Yang H, Spring Kong FM. Effect of radiation fractionation on IDO1 via the NF-κB/COX2 axis in non-small cell lung cancer. Int Immunopharmacol. 2023 Sep 24;124(Pt B):110956. doi: 10.1016/j.intimp.2023.110956. Epub ahead of print. PMID: 37751656.

    16: Chiang CL, Lam TC, Li JCB, Chan KSK, El Helali A, Lee YYP, Law LHT, Zheng D, Lo AWI, Kam NW, Li WS, Cheung AKW, Chow JCH, Chan SPC, Lai JWY, Lee SWM, Kong FS, Ng WT, Kwong DLW, Lee AWM. Efficacy, safety, and correlative biomarkers of bintrafusp alfa in recurrent or metastatic nasopharyngeal cancer patients: a phase II clinical trial. Lancet Reg Health West Pac. 2023 Sep 6;40:100898. doi: 10.1016/j.lanwpc.2023.100898. PMID: 37701718; PMCID: PMC10493598.

    17: Yang L, Xu Z, Ma L, Liu Q, Chang ATY, Wang Q, Zha J, Zhang J, Jiang X, Zhang J, Kong FS, Guo L. Early onset of severe lymphopenia during definitive radiotherapy correlates with mean body dose and predicts poor survival in cervical cancer. Cancer Biomark. 2022;34(1):149-159. doi: 10.3233/CBM-210292. PMID: 35094986; PMCID: PMC9108612.

    18: Nilsson M, Olafsdottir H, Alexandersson von Döbeln G, Villegas F, Gagliardi G, Hellström M, Wang QL, Johansson H, Gebski V, Hedberg J, Klevebro F, Markar S, Smyth E, Lagergren P, Al-Haidari G, Rekstad LC, Aahlin EK, Wallner B, Edholm D, Johansson J, Szabo E, Reynolds JV, Pramesh CS, Mummudi N, Joshi A, Ferri L, Wong RK, O'Callaghan C, Lukovic J, Chan KK, Leong T, Barbour A, Smithers M, Li Y, Kang X, Kong FM, Chao YK, Crosby T, Bruns C, van Laarhoven H, van Berge Henegouwen M, van Hillegersberg R, Rosati R, Piessen G, de Manzoni G, Lordick F. Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial. Front Oncol. 2022 Jul 13;12:917961. doi: 10.3389/fonc.2022.917961. PMID: 35912196; PMCID: PMC9326032.

    19: Xu L, Zou C, Zhang S, Chu TSM, Zhang Y, Chen W, Zhao C, Yang L, Xu Z, Dong S, Yu H, Li B, Guan X, Hou Y, Kong FM*. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. J Hematol Oncol. 2022 Jul 7;15(1):87. doi: 10.1186/s13045-022-01307-2. PMID: 35799264; PMCID: PMC9264569.

    20: Chen Z, Huang YH, Kong FM, Ho WY, Ren G, Cai J. A super-voxel-based method for generating surrogate lung ventilation images from CT. Front Physiol. 2023 Apr 26;14:1085158. doi: 10.3389/fphys.2023.1085158. PMID: 37179833; PMCID: PMC10171197